Compare DexCom, Inc. (DXCM) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares MSCI United Kingdom (FTSE) — how do they compare? DexCom, Inc. trades at $77.85 (market cap $28.06B), while iShares MSCI United Kingdom (FTSE) trades at $46.79. The key difference: iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | EWU | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $89.53 | $48.68 |
52-Week Low | $54.84 | $39.80 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
EWU trades at $46.79, up 1.04% with a bullish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at 62.29. Recent news highlights Middle East tensions impacting European markets, though energy sector gains provide some offset. Key support sits at $46 with resistance at $47.
The outlook remains cautiously optimistic given technical strength, though fundamental data is limited. Risks include geopolitical volatility and broader market sentiment. Investment opportunity hinges on UK economic recovery and energy sector performance amid current market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
